MYRIAD GENETICS, INC.
Myriad Genetics, Inc. is a Delaware corporation that is registered to transact business in Utah under registration number 1190599-0143 with the Utah Division of Corporations and Commercial Code, where its status is listed as active. The company was incorporated in Delaware on 6 November 1992 and is headquartered at 322 North 2200 West, Salt Lake City, Utah 84116, according to its filings with the U.S. Securities and Exchange Commission (SEC). Myriad Genetics, Inc. is a molecular diagnostics and precision-medicine company that develops and markets genetic and genomic tests used in oncology, women’s health, and psychiatric treatment planning.
The company’s principal test lines include hereditary cancer risk assessment (MyRisk Hereditary Cancer and BRACAnalysis), prenatal screening (Foresight and Prequel), tumor profiling and companion diagnostics that support treatment decisions with PARP-inhibitor therapies (MyChoice CDx), a prognostic test for prostate cancer (Prolaris), a minimal-residual-disease monitoring assay launched for a limited set of breast-cancer customers in March 2026 (Precise MRD), and a pharmacogenomic test used to guide psychiatric medication selection (GeneSight). Customers include oncologists and other physicians, health systems, and pharmaceutical companies that use Myriad Genetics, Inc.’s companion-diagnostic testing in drug development and patient selection. In April 2026, Japan’s Ministry of Health, Labour and Welfare approved use of the MyChoice CDx test as a companion diagnostic for a PARP-inhibitor therapy in prostate and ovarian cancer, extending its international regulatory approvals.
Myriad Genetics, Inc. common stock has traded on the Nasdaq Global Select Market under the ticker MYGN since its October 1995 initial public offering. For fiscal year 2025 (ended 31 December 2025), the company reported consolidated revenue of $824.5 million, a 2 percent decrease from fiscal year 2024, and employed approximately 2,700 people as of 19 February 2026, according to its Form 10-K filed with the SEC. For the first quarter of fiscal year 2026, the company reported revenue of $200.4 million, up 2 percent year-over-year. Its principal offices are in Salt Lake City, with additional operations across the United States and, through its business activities, in Europe and Japan.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Five institutional shareholders are disclosed for Myriad Genetics, Inc. in the registry data underlying this profile, drawn from SEC-reportable institutional holdings (Schedule 13F/13G) rather than a complete shareholder register, which is not published for Nasdaq-listed companies with dispersed public ownership. As of the most recent snapshot reflected in these filings (4 September 2026), the largest disclosed holder is Vanguard Group Inc, reporting 8,225,371 shares (approximately 11.6 percent). This figure matches the 8,225,371-share position that Vanguard Group Inc was independently reported to hold in its own SEC disclosure, corroborating the registry data for this holder. The other disclosed holders are iShares Trust – iShares Core S&P Small-Cap ETF (approximately 7.9 percent), iShares Trust – iShares Russell 2000 ETF (approximately 3.2 percent), Fidelity Salem Street Trust – Fidelity Small Cap Index Fund (approximately 1.3 percent), and iShares Trust – iShares Russell 2000 Value ETF (approximately 1.1 percent). All five disclosed holders are passive index or institutional funds rather than individuals. A separate Schedule 13G/A filed with the SEC shows BlackRock, Inc. also held a major position of 7,976,163 shares (approximately 8.5 percent) as of 31 March 2026, a holding not captured in the registry snapshot above, confirming that the disclosed list reflects major shareholders only rather than the company’s complete shareholder base.
Data availability
Shareholder information for Myriad Genetics, Inc. is classified as major shareholders only: as a Nasdaq-listed public company, it discloses beneficial ownership only for holders that cross SEC reporting thresholds or that file Schedule 13F institutional holdings reports, not its full shareholder base. No verified ultimate beneficial owner is identified, because every disclosed shareholder is an institutional investment fund rather than a natural person, and a complete ownership chain to an individual cannot be established from these filings.
Sources
- Myriad Genetics, Inc. registry shareholder data (institutional holdings, Schedule 13F/13G basis); retrieval date 4 September 2026.
- U.S. Securities and Exchange Commission, EDGAR filings index for Myriad Genetics, Inc. (CIK 0000899923), Schedule 13G/13G-A filings – sec.gov; includes Vanguard Group Inc and BlackRock, Inc. disclosures; retrieved 11 September 2026.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Vanguard Group Inc | 11.6% | Utah Division of Corporations and Commercial Code | |
| iShares Trust-iShares Core S&P Small-Cap ETF | 7.9% | Utah Division of Corporations and Commercial Code | |
| iShares Trust-iShares Russell 2000 ETF | 3.2% | Utah Division of Corporations and Commercial Code | |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.3% | Utah Division of Corporations and Commercial Code | |
| iShares Trust-iShares Russell 2000 Value ETF | 1.1% | Utah Division of Corporations and Commercial Code |
Officers
5
Myriad Genetics, Inc. discloses its directors and executive officers through SEC filings and investor communications rather than through a state company register. As of its current corporate governance disclosures, the Board of Directors comprises eight members: S. Louise Phanstiel (Chair of the Board, a director since September 2009), President and Chief Executive Officer Sam Raha, and non-employee directors Paul M. Bisaro, Mark S. Davis, Heiner Dreismann, Rashmi Kumar, Lee N. Newcomer, and Colleen F. Reitan. Named executive officers include Sam Raha (President and Chief Executive Officer, since 30 April 2025), R. Bryan Riggsbee (Executive Vice President, Chief Financial Officer and Treasurer, in the role since October 2014), and Mark S. Verratti (Chief Operating Officer, since 30 April 2025). No officer or director covered here is recorded as resigned or removed in the sources reviewed; all are current appointments. Nationality and country of residence are not disclosed for any officer or director in these sources.
Recent officer changes
- Paul J. Diaz stepped down as President and Chief Executive Officer, and Sam Raha, previously Chief Operating Officer, was appointed President, Chief Executive Officer and a director, both effective 30 April 2025 (source: Myriad Genetics, Inc. Form 8-K, U.S. Securities and Exchange Commission).
- Mark S. Verratti, previously Chief Commercial Officer, was promoted to Chief Operating Officer effective 30 April 2025, concurrent with Mr. Raha’s appointment (source: same Form 8-K).
- Mark S. Davis was elected to the Board of Directors effective 10 December 2024 (source: Myriad Genetics, Inc. press release, GlobeNewswire, 10 December 2024).
Data availability
Officer and director information for Myriad Genetics, Inc. is fully public, since the company is subject to SEC proxy and disclosure rules and publishes current governance details through its investor relations site and periodic filings. This overview is based on those sources rather than the officer records shown elsewhere in this profile, which include role titles – for example, more than one individual recorded as holding the board chair title – that could not be corroborated against the company’s current SEC filings or investor relations disclosures and have therefore not been relied upon here.
Sources
- Myriad Genetics, Inc., Corporate Governance – investor.myriad.com/corporate-governance; retrieved 11 September 2026.
- Myriad Genetics, Inc., Form 8-K (leadership transition), U.S. Securities and Exchange Commission – sec.gov; effective 30 April 2025, retrieved 11 September 2026.
- Myriad Genetics, Inc., “Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member,” GlobeNewswire – globenewswire.com; published 10 December 2024, retrieved 11 September 2026.
Group Structure
Myriad Genetics, Inc. is a publicly traded Delaware corporation. No parent company or controlling shareholder is identified in its SEC filings; the company is itself the top entity in its corporate group. Its List of Subsidiaries of the Registrant (Exhibit 21.1), filed with its Form 10-K for the year ended 31 December 2025, identifies eight wholly-owned subsidiaries: four incorporated in Delaware, United States (Myriad Genetic Laboratories, Inc.; Assurex Health, Inc.; Gateway Genomics, LLC; and Myriad Women’s Health, Inc.) and four incorporated outside the United States (Myriad GmbH in Germany, Myriad Genetics GmbH in Switzerland, Myriad Genetics B.V. in the Netherlands, and Myriad Genetics GK in Japan). This differs from the parent-subsidiary linkage shown elsewhere in this profile, which lists Myriad Genetics GmbH as sitting above Myriad Genetics, Inc. in the ownership chain – the reverse of the relationship confirmed in the company’s own SEC exhibit. That linkage could not be corroborated against SEC filings and has not been relied upon in this section.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Myriad Genetic Laboratories, Inc. | United States (Delaware) | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Assurex Health, Inc. | United States (Delaware) | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Gateway Genomics, LLC | United States (Delaware) | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Myriad Women’s Health, Inc. | United States (Delaware) | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Myriad GmbH | Germany | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Myriad Genetics GmbH | Switzerland | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Myriad Genetics B.V. | Netherlands | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
| Myriad Genetics GK | Japan | Not disclosed | Direct subsidiary | Wholly owned | Active | FY2025 Form 10-K |
The Exhibit 21.1 filing describes each of these entities as a wholly-owned subsidiary of Myriad Genetics, Inc. but does not specify whether this reflects share capital, voting rights, or another basis of control, and it does not disclose registration numbers.
Data availability
Corporate-linkage information for Myriad Genetics, Inc. is full at the parent level (no parent identified, consistent with its status as a publicly traded company) and partial at the subsidiary level: subsidiary names and jurisdictions are disclosed, but registration numbers and the precise ownership basis are not itemised in the source exhibit.
Sources
- Myriad Genetics, Inc., Form 10-K for the fiscal year ended 31 December 2025, Exhibit 21.1 “List of Subsidiaries of the Registrant,” U.S. Securities and Exchange Commission – sec.gov; filed February 2026, retrieved 11 September 2026.
Myriad Genetics GmbH
Switzerland
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does MYRIAD GENETICS, INC. do?
Myriad Genetics, Inc. is a Delaware corporation registered to do business in Utah (registration number 1190599-0143), headquartered in Salt Lake City. It develops and markets molecular diagnostic and precision-medicine tests for hereditary cancer risk, prenatal screening, tumor profiling, prostate cancer prognosis, and psychiatric medication selection.
Who owns MYRIAD GENETICS, INC.?
SEC filings show Myriad Genetics, Inc.'s largest disclosed institutional shareholders include Vanguard Group Inc (about 11.6 percent, 8,225,371 shares) and BlackRock, Inc. (about 8.5 percent, 7,976,163 shares), among other index and institutional funds. Disclosed holdings reflect only SEC-reportable positions, not the company's complete shareholder base.
Who is MYRIAD GENETICS, INC.'s UBO (Ultimate Beneficial Owner)?
No natural-person ultimate beneficial owner is identified for Myriad Genetics, Inc.; its disclosed major shareholders are all institutional investment funds rather than individuals.
What is MYRIAD GENETICS, INC.'s company registration number?
MYRIAD GENETICS, INC.'s registration number is 1190599-0143, filed with Utah Division of Corporations and Commercial Code in United States. Its current status on the register is active.
Is MYRIAD GENETICS, INC. still an active company?
MYRIAD GENETICS, INC.'s status on Utah Division of Corporations and Commercial Code is listed as active.
When was MYRIAD GENETICS, INC. incorporated?
MYRIAD GENETICS, INC. was incorporated on 8 December 1992, according to Utah Division of Corporations and Commercial Code.
What is MYRIAD GENETICS, INC.'s registered address?
The registered address on file for MYRIAD GENETICS, INC. is Salt Lake City, United States.
What legal structure is MYRIAD GENETICS, INC. registered as?
MYRIAD GENETICS, INC. is registered as a Private limited company (Ltd.) in United States.
What is MYRIAD GENETICS, INC.'s revenue?
Myriad Genetics, Inc. reported consolidated revenue of 824.5 million US dollars for fiscal year 2025, a 2 percent decrease from fiscal year 2024.
Is MYRIAD GENETICS, INC. listed on a stock exchange?
Myriad Genetics, Inc. common stock has traded on the Nasdaq Global Select Market under the ticker MYGN since its October 1995 initial public offering.
Who are the officers/directors of MYRIAD GENETICS, INC.?
The Board of Directors of Myriad Genetics, Inc. is chaired by S. Louise Phanstiel. Sam Raha has served as President and Chief Executive Officer since 30 April 2025, succeeding Paul J. Diaz.
Does MYRIAD GENETICS, INC. have a parent company or subsidiaries?
Myriad Genetics, Inc. has no identified parent company. Per its SEC Exhibit 21.1 filing, it is the top entity in its corporate group, with eight wholly-owned subsidiaries in the United States, Germany, Switzerland, the Netherlands, and Japan.
Can Zavia monitor changes to MYRIAD GENETICS, INC.'s ownership over time?
This profile reflects a point-in-time snapshot from Utah Division of Corporations and Commercial Code. Zavia's monitoring API can track changes to MYRIAD GENETICS, INC.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access MYRIAD GENETICS, INC.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United States, so records like MYRIAD GENETICS, INC.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Utah Division of Corporations and Commercial Code and was last synced on 9 September 2026.